Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last --
Change Today 0.00 / 0.00%
Volume 0.0
RANBAXY On Other Exchanges
Symbol
Exchange
RANBAXY is not on other exchanges.
All times are local (Market data is delayed by at least 15 minutes).

ranbaxy laboratories ltd (RANBAXY) Snapshot

Open
--
Previous Close
--
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
0.0
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for RANBAXY LABORATORIES LTD (RANBAXY)

Related News

No related news articles were found.

ranbaxy laboratories ltd (RANBAXY) Related Businessweek News

View More BusinessWeek News

ranbaxy laboratories ltd (RANBAXY) Details

Ranbaxy Laboratories Limited, a pharmaceutical company, develops, manufactures, and markets pharmaceutical products. The company offers generics, differentiated products, over-the-counter products, anti-retrovirals, active pharmaceutical ingredients, and intermediates. Its products are used for the treatment in various therapy areas, including anti-infectives, cardiovascular, pain and musculoskeletal, central nervous system, gastrointestinal, respiratory, anti-retrovirals, dermatology, orthopaedics, nutritionals, urology, and diabetes. The company offers a portfolio of approximately 500 molecules in the forms of tablets, capsules, injectables, inhalers, ointments, creams, and liquids. Ranbaxy Laboratories Limited operates in India, Europe, North America, the Asia Pacific, and Africa. The company was founded in 1961 and is headquartered in New Delhi, India. Ranbaxy Laboratories Limited is a subsidiary of Daiichi Sankyo Company, Ltd.

15,300 Employees
Last Reported Date: 07/1/14
Founded in 1961

ranbaxy laboratories ltd (RANBAXY) Top Compensated Officers

Chief Executive Officer, Managing Director, E...
Total Annual Compensation: 122.7M
Compensation as of Fiscal Year 2014.

ranbaxy laboratories ltd (RANBAXY) Key Developments

US FDA Cancels Approval for Two Ranbaxy Drugs in United States

Approvals granted to Ranbaxy by the US Food and Drug Administration (USFDA) for marketing generic versions of two blockbuster medicines and the 180-day marketing exclusivity stand cancelled. The DC Federal Court in the US has upheld the USFDA's decision to revoke tentative approvals given to the company for the generic versions of AstraZeneca's digestive disorder drug Nexium and Roche's antiviral Valcyte. In November last year, Ranbaxy had sued USFDA over revoking an approval to sell the generic drugs.

Ranbaxy Labs Ltd. Presents at BIO-Europe Spring 2015, Mar-09-2015

Ranbaxy Labs Ltd. Presents at BIO-Europe Spring 2015, Mar-09-2015 . Venue: Paris Expo - Porte de Versailles, Hall 5, Paris, France.

Ranbaxy Laboratories Ltd. Reports Unaudited Consolidated and Standalone Financial Results for the Fourth Quarter and Year Ended December 31, 2014

Ranbaxy Laboratories Ltd. reported unaudited consolidated and standalone financial results for the fourth quarter and year ended December 31, 2014. For the quarter, on consolidated basis, the company’s total income from operations (net) was INR 26,188.46 million against INR 28,939.92 million a year ago. Profit from operations before other income, finance costs and exceptional items was INR 161.24 million against INR 1,788.42 million a year ago. Loss from ordinary activities before tax was INR 1,354.13 million against INR 603.49 million a year ago. Net loss for the period was INR 10,236.05 million against INR 1,584.89 million a year ago. Diluted loss per share was INR 24.26 against INR 3.76 a year ago. Sales were INR 25,876 million against INR 28,590 million a year ago. Earnings before interest, tax, depreciation & amortization (EBITDA) were INR 1,129 million. For the full year, standalone total income from operations (net) was INR 82,953.66 million against INR 83,298.30 million a year ago. Profit from operations before other income, finance costs and exceptional items was INR 8,517.77 million against INR 3,679.16 million a year ago. Profit from ordinary activities before tax was INR 2,354.32 million against loss from ordinary activities before tax of INR 9,384.00 million a year ago. Net loss for the period was INR 7,323.11 million against INR 11,246.46 million a year ago. Diluted loss per share was INR 17.41 against INR 26.89 a year ago. Sales were INR 81,778 million against INR 81,931 million a year ago. Earnings before interest, tax, depreciation & amortization (EBITDA) was INR 11,579 million. For the quarter, on standalone basis, the company’s total income from operations (net) was INR 10,098.49 million against INR 13,665.63 million a year ago. Loss from operations before other income, finance costs and exceptional items was INR 4,063.15 million against INR 1,118.96 million a year ago. Loss from ordinary activities before tax was INR 5,651.35 million against INR 3,959.60 million a year ago. Net loss for the period was INR 14,204.85 million against INR 3,959.60 million a year ago. Diluted loss per share was INR 33.47 against INR 9.36 a year ago. For the full year, on standalone basis, the company’s total income from operations (net) was INR 44,971.58 million against INR 42,312.84 million a year ago. Profit from operations before other income, finance costs and exceptional items was INR 2,386.94 million against loss from operations before other income, finance costs and exceptional items of INR 5,035.98 million a year ago. Loss from ordinary activities before tax was INR 1,690.32 million against INR 18,470.01 million a year ago. Net loss for the period was INR 10,336.19 million against INR 18,470.01 million a year ago. Diluted loss per share was INR 24.38 against INR 43.67 a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RBXY:IN 805.20 INR 0.00

RANBAXY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Aurobindo Pharma Ltd 1,205 INR +70.35
Cadila Healthcare Ltd 1,655 INR -7.20
Richter Gedeon Nyrt 3,952 -68.00
Cipla Ltd/India 694.00 INR -6.95
Dabur India Ltd 264.80 INR +2.05
View Industry Companies
 

Industry Analysis

RANBAXY

Industry Average

Valuation RANBAXY Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 3.2x
Price/Book 9.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 2.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact RANBAXY LABORATORIES LTD, please visit www.ranbaxy.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.